Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
Mayo Clinic
Washington University School of Medicine
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Washington University School of Medicine
National Cancer Institute (NCI)
Northwestern University
Huashan Hospital
Jonsson Comprehensive Cancer Center
McGill University Health Centre/Research Institute of the McGill University Health Centre
Institut Claudius Regaud
Activartis Biotech
Duke University
INSYS Therapeutics Inc
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Shandong Lanjin Pharmaceuticals Co.,Ltd
INSYS Therapeutics Inc
INSYS Therapeutics Inc
INSYS Therapeutics Inc
INSYS Therapeutics Inc
Soroka University Medical Center